Penumbra, Inc. Appoints Shruthi Narayan as President to Lead Growth and Innovation

Penumbra, Inc. Names Shruthi Narayan as Company President

Penumbra, Inc. (NYSE: PEN), recognized as a global leader in thrombectomy solutions, has recently announced the promotion of Shruthi Narayan to the position of President, effective September 1, 2025. In this pivotal role, Ms. Narayan will continue to report to Adam Elsesser, who previously held the office of President and will maintain his roles as both chairman and chief executive officer.

Mr. Elsesser had high praise for Ms. Narayan, stating, "She is a dynamic and experienced leader whose passion for innovation and proven capability to inspire global teams makes her the ideal candidate for this crucial position. Her vision and commitment to excellence are sure to propel Penumbra’s remarkable growth and solidify our leadership in the market, ensuring our life-saving technologies reach patients worldwide."

With over 20 years in the medical device industry, Ms. Narayan has been instrumental in driving significant progress within Penumbra. Prior to her new appointment, she served as the president of the company’s interventional business, where she oversaw day-to-day operations along with growth strategies for both the neuro and vascular franchises. Since joining Penumbra in 2013 as a product manager, she has played a key role in various capacities, helping to establish the peripheral vascular division and globalizing the company's thromboembolism and thrombectomy product lineup.

Her career launched in 2006 at Medtronic, where she garnered experience in engineering, regulatory affairs, and cardiovascular sales. Ms. Narayan holds a Bachelor of Science in Electrical Engineering from Anna University in India and a Master’s degree in Biomedical Engineering from the University of Southern California, emphasizing medical device commercialization.

Commenting on her new role, Ms. Narayan expressed her dedication to advancing patient care, stating, "Penumbra has been at the forefront of blood clot management for over 20 years, delivering groundbreaking technologies to treat conditions ranging from strokes to pulmonary embolisms. It is an honor to lead this charge and further expand our legacy of innovation, as we continue to shift the paradigm in patient care."

Penumbra is recognized for developing pioneering technologies aimed at addressing complicated medical conditions such as ischemic strokes, venous thromboembolism like pulmonary embolisms, and acute limb ischemia. The company’s extensive portfolio includes cutting-edge computer-assisted vacuum thrombectomy (CAVT) systems, aiming to swiftly and safely remove blood clots from various locations in the body. Operating in over 100 countries, Penumbra collaborates with healthcare providers to enhance patient outcomes and overall quality of life.

As the company steps forward under Ms. Narayan's leadership, Penumbra is set to continue its commitment to innovation and excellence in the medical device sector, helping to improve the lives of countless patients.

For more information about Penumbra and its products, visit www.penumbrainc.com and connect with them on Instagram, LinkedIn, and X.